| Literature DB >> 29787589 |
Yue Feng1, Yue-Mei Feng2,3, Songmei Wang2,3, Fang Xu2,3, Xuehui Zhang2,3, Chunyue Zhang1, Yuanyuan Jia1, Wanru Yang1, Xueshan Xia1, Jianzhong Yin2,3.
Abstract
Hepatitis E virus (HEV) infection is relatively high in the southern regions of China. Yunnan, located in southwestern China, has the highest number of ethnic groups. However, HEV infection in the ethnic population is largely unknown. Therefore, we aimed to investigate the seropositive rate, risk factor, and clinical impact of HEV infection in the ethnic groups of Yunnan. We recruited 1912 individuals from four minority groups in three prefectures of Yunnan province. Epidemiological records on potential risk factors for exposure to HEV and blood biochemical index were analyzed. All the serum samples were tested for anti-HEV IgM/IgG by enzyme-linked immunosorbent assay, and the IgM-positive samples were subjected to nested reverse transcription-PCR to detect HEV RNA. Overall, 1273 individuals (66.58%) were positive for anti-HEV IgG, 16 (0.84%) for anti-HEV IgM, and 64 (3.35%) for anti-HEV IgG and IgM both; none of them had detectable HEV RNA. Multivariate analysis revealed a strong statistical association between ethnic origin and HEV IgG seroprevalence. Anti-HEV IgG reactivity in the Hani ethnic (82.3%; 401/487) population was higher than that in the Naxi (71.9%, 340/473), Bulang (65.1%; 302/464), and Wa (60.2%; 294/488) ethnic populations (p < 0.0001). Older age and male sex were independently associated with the risk of past HEV infection. Moreover, anti-HEV IgG-positive individuals showed significantly higher levels of total and direct bilirubin and alanine amino transferase but significantly lower levels of globulin and low-density lipoprotein, than the respective levels in anti-HEV IgG-negative individuals. Thus, the seroprevalence of HEV infection is high in the ethnic populations of Yunnan, China. It is therefore necessary to increase the surveillance of specific risk groups and raise awareness about the possible infectious diseases to help limit the HEV transmission here.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29787589 PMCID: PMC5963781 DOI: 10.1371/journal.pone.0197577
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Maps of the study region and geographical distribution of subjects from all three prefectures of the Yunnan province of southwestern China.
The Yunnan province of southwestern China is marked in dark gray, the Lijiang prefecture, Lincang prefecture, and Honghe prefecture are highlighted in light gray, respectively. MYA: Myanmar; THA: Thailand; LAO: Laos; VIE: Vietnam.
Fig 2Comparison of anti-HEV IgM/IgG seropositity distributions among four different ethnic groups in Yunnan, China.
The different seropositivities are shown in different colors, the anti-HEV IgG+ is marked in gray, anti-HEV IgM+ is highlighted in dark blue, and anti-HEV IgG and IgM co-positive is marked in red.
Results from logist regression of anti-HEV IgG seropositity.
| Variable | No.tested | HEV IgG seropositive | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|---|---|
| n | %(95% CI) | OR (95% CI) | p-value | OR (95% CI) | p-value | ||
| Male | 800 | 588 | 73.5 (70.4–76.6) | 1 | |||
| Female | 1112 | 749 | 67.4 (64.6–70.1) | 0.744 (0.609–0.909) | 0.004 | 0.707 (0.572–0.875) | 0.001 |
| ≤30 | 235 | 104 | 44.3 (37.9–50.6) | 1 | |||
| 31–45 | 561 | 364 | 64.9 (60.9–68.8) | 2.327(1.706–3.174) | <0.001 | 2.123(1.541–2.925) | <0.000 |
| 46–60 | 695 | 541 | 77.8 (74.8–80.9) | 4.425(3.234–6.055) | <0.001 | 4.013(2.903–5.548) | <0.001 |
| >60 | 421 | 328 | 77.9 (73.9–81.9) | 4.443(3.145–6.275) | <0.001 | 4.489(3.107–6.485) | <0.001 |
| Wa | 488 | 294 | 60.2 (55.9–64.6) | 1 | |||
| Bulang | 464 | 302 | 65.1 (60.7–69.4) | 1.230(0.945–1.601) | 0.123 | 1.336(1.015–1.758) | 0.039 |
| Naxi | 473 | 340 | 71.9 (67.8–75.9) | 1.687(1.287–2.210) | <0.001 | 1.571(1.175–2.100) | 0.002 |
| Hani | 487 | 401 | 82.3 (79.0–85.7) | 3.077(2.290–4.133) | <0.001 | 2.969(2.188–4.030) | <0.001 |
| Illiterate | 746 | 553 | 74.1 (71.0–77.3) | 1 | |||
| Primary | 713 | 492 | 69.0 (65.6–72.4) | 0.777(0.618–0.976) | 0.03 | ||
| Secondary | 350 | 233 | 66.6 (61.6–71.5) | 0.695(0.527–0.916) | 0.01 | ||
| College and above | 103 | 59 | 57.3 (47.7–66.8) | 0.468(0.306–0.715) | <0.001 | ||
| Low | 1393 | 986 | 70.8 (68.4–73.2) | 1 | |||
| Medium | 519 | 351 | 67.6 (63.6–71.7) | 0.862 (0.694–1.072) | 0.182 | ||
| No | 1130 | 780 | 69.0 (66.3–71.7) | 1 | |||
| Yes | 782 | 557 | 71.2 (68.1–74.4) | 1.111 (0.910–1.356) | 0.302 | ||
| No | 1279 | 864 | 67.6 (65.0–70.1) | 1 | |||
| Yes | 633 | 473 | 74.7 (71.3–78.1) | 1.420 (1.146–1.759) | 0.001 | ||
| Normal | 688 | 467 | 67.9 (64.4–71.4) | 1 | |||
| High | 1224 | 870 | 71.1 (68.5–73.6) | 1.163 (0.950–1.424) | 0.143 | 1.399 (1.109–1.765) | 0.005 |
Education level, IIIiterate: no education; Primary: 1–6 years of education; Secondary: 7–9 years; College and above: more than 9 years.
Socio-economic level, Low: less than 30,000 RBM of average annual income; Medium: 30,000–50,000 RBM.
Drinking, No: never or occasionally drink; Yes: often or every day.
Smoking, No: never or occasionally smoke; Yes: often or every day.
Labor intensity, Normal: no exhaustion; High: exhaustion.
Blood biochemical characteristics of ethnic minority populations acoording to anti-HEV IgG status.
| Biochemistry indexes | Anti-HEV IgG positive N = 1337 | Anti-HEV IgG negative N = 575 | p-value | |
|---|---|---|---|---|
| Total bilirubin (umol/L) | 6.59 ± 4.14 | 6.34 ± 3.94 | ||
| Direct bilirubin (umol/L) | 3.07 ± 1.55 | 2.90 ± 1.50 | ||
| Indirect bilirubin (umol/L) | 3.52 ± 2.93 | 3.44 ± 2.79 | 0.5504 | |
| Total protein (g/L) | 73.67 ± 5.36 | 73.87 ± 5.24 | 0.4797 | |
| Albumin (g/L) | 41.73 ± 3.18 | 41.45 ± 3.15 | 0.0554 | |
| Globulin (g/L) | 31.93 ± 3.63 | 32.43 ± 3.47 | ||
| A/G | 1.32 ± 0.17 | 1.29 ± 0.16 | ||
| Alanine amino transferase (U/L) | 15.47 ± 9.70 | 14.58 ± 9.28 | ||
| Aspartate amino transferase (U/L) | 27.60 ± 16.61 | 27.13 ± 14.66 | 0.9837 | |
| AST/ALT | 2.29 ± 1.71 | 2.44 ± 2.09 | 0.0282 | |
| Alkaline phosphatase (U/L) | 78.34 ± 26.40 | 78.74 ± 26.96 | 0.9626 | |
| Glutamyl transpeptadase (U/L) | 46.18 ± 91.40 | 43.81 ± 73.38 | 0.2702 | |
| Urea (umol/L) | 5.16 ± 1.44 | 5.12 ± 1.47 | 0.5257 | |
| Creatinine (umol/L) | 73.28 ± 14.38 | 73.06 ± 14.70 | 0.7119 | |
| Uric acid (umol/L) | 256.59 ± 66.02 | 257.85 ± 66.71 | 0.8172 | |
| Glucose (mmol/L) | 4.83 ± 1.03 | 4.80 ± 1.15 | 0.1494 | |
| Total cholesterol (mmol/L) | 4.88 ± 1.04 | 4.92 ± 1.01 | 0.3903 | |
| Triglyceride (mmol/L) | 2.14 ± 1.51 | 2.06 ± 1.44 | 0.2492 | |
| High density lipoprotein (mmol/L) | 1.34 ± 0.31 | 1.34 ± 0.31 | 0.8038 | |
| Low density lipoprotein (mmol/L) | 2.77 ± 0.81 | 2.85 ± 0.83 | ||